EP2452701A1 - Instrument médical pour administrer un médicament - Google Patents

Instrument médical pour administrer un médicament Download PDF

Info

Publication number
EP2452701A1
EP2452701A1 EP10811665A EP10811665A EP2452701A1 EP 2452701 A1 EP2452701 A1 EP 2452701A1 EP 10811665 A EP10811665 A EP 10811665A EP 10811665 A EP10811665 A EP 10811665A EP 2452701 A1 EP2452701 A1 EP 2452701A1
Authority
EP
European Patent Office
Prior art keywords
drug
medical device
phospholipid
drug delivery
paclitaxel
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP10811665A
Other languages
German (de)
English (en)
Other versions
EP2452701A4 (fr
Inventor
Yuuji Nakagawa
Masakazu Shimoyama
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Terumo Corp
Original Assignee
Terumo Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Terumo Corp filed Critical Terumo Corp
Publication of EP2452701A1 publication Critical patent/EP2452701A1/fr
Publication of EP2452701A4 publication Critical patent/EP2452701A4/fr
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M25/00—Catheters; Hollow probes
    • A61M25/0043—Catheters; Hollow probes characterised by structural features
    • A61M25/0045—Catheters; Hollow probes characterised by structural features multi-layered, e.g. coated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L29/00—Materials for catheters, medical tubing, cannulae, or endoscopes or for coating catheters
    • A61L29/14—Materials characterised by their function or physical properties, e.g. lubricating compositions
    • A61L29/16—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L31/16—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M25/00—Catheters; Hollow probes
    • A61M25/0009—Making of catheters or other medical or surgical tubes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/416—Anti-neoplastic or anti-proliferative or anti-restenosis or anti-angiogenic agents, e.g. paclitaxel, sirolimus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M25/00—Catheters; Hollow probes
    • A61M25/0043—Catheters; Hollow probes characterised by structural features
    • A61M2025/0057—Catheters delivering medicament other than through a conventional lumen, e.g. porous walls or hydrogel coatings

Definitions

  • a medical device for drug delivery and a medical device for drug delivery which is so designed as to deliver a drug to a site of treatment for local administration in order to cure the stenosis, occlusion, or arteriosclerotic plaque which has occurred in the lumen of the living body.
  • PTA Percutaneous Transluminal Angioplasty
  • PTCA Percutaneous Transluminal Coronary Angioplasty
  • PCI Percutaneous Transluminal Coronary Intervention
  • POBA Plain Old Balloon Angioplasty
  • a stent which is a small hollow tubular object.
  • the indwelling stent in the blood vessel can successfully prevent acute coronary occlusion but can allow restenosis to occur at a rate of 20 to 30%.
  • DES Drug Eluting Stent
  • DES has posed a new problem with delayed stent thrombosis that can occur more than one year after its placement. This problem has attracted serious attention in the medical world. See, for example, McFadden EP, Lancet, 2004; 364: 1519-1521 .
  • a possible reason for the stent thrombosis is that the drug supported on the stent hampers not only the growth of smooth muscle cells but also the formation of nascent intima including endothelial cells.
  • Other factors can include hypersensitivity to the polymer as the carrier of the drug and imperfect stent placement. See, for example, Joner M, J. Am. Coll. Cardiol., 2006; 48: 193-202 .
  • the foregoing problem can arise basically from the fact that the stent, drug, and polymer used for DES remain in the living body for a long period of time, thereby continuously stimulating the blood vessel for a long period of time.
  • the delayed stent thrombosis can end up with critical situations including frequent cardiac infarction and even death once it occurs. Hence it can be beneficial to provide an adequate countermeasure.
  • a clinical practice to reduce the risk of delayed stent thrombosis is chronic administration of antiplatelet drug, and improved tools for this purpose are appearing as listed below.
  • an approach is under way to prevent restenosis only by delivering a drug through a balloon catheter without resorting to the indwelling stent or polymer which can cause the delayed stent thrombosis.
  • One way of achieving such an approach is by using a balloon catheter having its balloon surface coated with a composition composed of an anticancer drug (paclitaxel) and a contrast medium (iopromide), the balloon catheter being known as a drug-elution balloon and allowing the drug to migrate to the blood vessel wall of the stenosis part in a short time as the balloon expands.
  • paclitaxel an anticancer drug
  • iopromide contrast medium
  • the contrast medium which is used in combination with the drug, has a high risk of serious side effects such as dyspnea, sudden pressure reduction, cardiac arrest, and loss of consciousness.
  • the contrast medium can be soluble in water and hence can be liable to dissolve in blood together with the drug coating the balloon surface, thereby preventing the effective delivery of the drug to the lesion.
  • a medical device for safe and sure delivery of a drug to the lesion.
  • the present inventors have found that the drug can improve in solubility and effectively migrate into the lumen wall tissue, for example, if it is incorporated with a phospholipid capable of molecular-level dispersion of the drug therein and forming a solid dispersion.
  • the present inventors After research of the solid dispersion composed of a drug and a phospholipid, the present inventors also found an exemplary solid dispersion compound that is extremely safe and easily wettable albeit insoluble or hardly soluble in water.
  • a medical device for drug delivery according to the following exemplary aspects (1) to (11):
  • a medical device for drug delivery which has at least a part of its surface in contact with the lumen wall tissue of a living body coated with a drug releasing layer containing a drug and a phospholipid, the drug and the phospholipid forming a solid dispersion.
  • the phospholipid is at least one species selected from the group consisting of phosphatidylcholine, phosphatidylglycerol, phosphatidic acid, phosphatidylethanolamine, phosphatidylserine, phosphatidylinositol, phosphatidylinositol polyphosphoric acid, sphingomyelin, cardiolipin, partially hydrogenated product thereof, and completely hydrogenated product thereof.
  • the drug is at least one species selected from the group consisting of anticancer drug, immunosuppressive drug, antibiotic, antirheumatic drug, antithrombotic drug, HMG-CoA reductase inhibitor, insulin resistance improver, ACE inhibitor, calcium antagonist, antihyperlipidemic drug, integrin inhibitor, antiallergic drug, antioxidant, GP IIb/IIIa antagonist, retinoid, flavonoid, carotenoid, lipid improver, DNA synthesis inhibitor, tyrosine kinase inhibitor, antiplatelet drug, antiinflammatory drug, tissue-derived biomaterial, interferon, and nitrogen monoxide generation promoting substance.
  • the drug is at least one species selected from the group consisting of anticancer drug, immunosuppressive drug, antibiotic, antirheumatic drug, antithrombotic drug, HMG-CoA reductase inhibitor, insulin resistance improver, ACE inhibitor, calcium antagonist, antihyperlipidemic drug, integrin inhibitor, antiallergic drug, antioxidant, GP IIb/IIIa antagonist,
  • a method for producing the medical device for drug delivery including applying a solution of a drug and a phospholipid dissolved in an organic solvent and subsequently removing the solvent by evaporation, thereby forming a drug releasing layer on at least part of the surface that comes into contact with the lumen wall tissue of the living body.
  • An exemplary medical device for drug delivery has the drug-releasing layer which contains a drug and a phospholipid, the latter being a low-molecular weight compound capable of molecular-level dispersion of the drug therein, thereby forming a solid dispersion.
  • the solid dispersion can be highly safe and can permit the drug to easily dissolve in and effectively migrate into the lumen wall tissue of the living body.
  • a medical device for drug delivery which has at least a part of its surface in contact with the lumen wall tissue of a living body coated with a drug releasing layer containing a drug and a phospholipid, the drug and the phospholipid forming a solid dispersion.
  • the phospholipid can have adequately controlled water solubility and wettability owing to, for example, its well-balanced hydrophilicity and lipophilicity to be bonded for the phosphate ester moiety and the fatty acid moiety. It is exemplified by hydrogenated soybean lecithin, which is commonly available. For example, this lecithin is hardly soluble in water but wettable when wet, so that the phospholipid forms, in combination with a drug, a hardly water-soluble solid dispersion which can prevent the drug from dissolving in blood when the medical device for drug delivery approaches the lesion percutaneously and intravenously.
  • the solid dispersion can become wet with water in blood, thereby increasing in viscosity, so that it helps the medical device for drug delivery to adhere to the surface of the lumen wall tissue when it comes into contact with the lumen wall tissue at the lesion.
  • the solid dispersion can adhere to the surface of the lumen wall tissue and stay there without being carried off by blood and releases the drug into the tissue.
  • the phospholipid for example, that of monomolecular compound, can be easily soluble in the cell membrane so that it permits the drug to migrate efficiently into cells.
  • the above-mentioned phospholipid can be an extremely safe compound in view of the fact that it exists in the living body as a constituent of the cell membrane and it is an approved pharmaceutical additive and food additive (as in the case of soybean lecithin) and it can be made into liposomes for clinical use.
  • the solid dispersion composed of a drug and a phospholipid can exist entirely or partly on the surface of the hollow expandable body. As the hollow expandable body comes into contact with the arteriosclerotic plaque in the lumen, the drug and the phospholipid can migrate into the cells of the lumen wall tissue.
  • the solid dispersion composed of a drug and a phospholipid can exist entirely or partly on the surface of the balloon.
  • the solid dispersion composed of the drug and the phospholipid can migrate into the cells of the lumen wall tissue.
  • the drug may be selected without specific restrictions so long as, for example, it treats or cures the stenosis, occlusion, or arteriosclerotic plaque which has occurred in the lumen of the living body.
  • the drug can be hardly soluble or insoluble in water from the standpoint of its limited elution into blood.
  • the drug can be at least one species selected from the group including anticancer drug, immunosuppressive drug, antibiotic, antirheumatic drug, antithrombotic drug, HMG-CoA reductase inhibitor, insulin resistance improver, ACE inhibitor, calcium antagonist, antihyperlipidemic drug, integrin inhibitor, antiallergic drug, antioxidant, GP IIb/IIIa antagonist, retinoid, flavonoid, carotenoid, lipid improver, DNA synthesis inhibitor, tyrosine kinase inhibitor, antiplatelet drug, antiinflammatory drug, tissue-derived biomaterial, interferon, and nitrogen monoxide generation promoting substance.
  • the drugs listed above can control the behavior of the cells of the lesion tissue and treat or cure the lesion.
  • the anticancer drug can include, for example, vincristine, vinblastine, vindesine, irinotecan, pirarubicin, paclitaxel, docetaxel, methotrexate and the like,
  • the immunosuppressive drug can include, for example, sirolimus and derivatives thereof, such as everolimus, pimecrolimus, ABT-578, AP23573, and CCI-779; tacrolimus, azathioprine, cyclosporine, cyclophosphamide, mycophenolate mofetil, gusperimus, mizoribine and the like.
  • the antibiotic can include, for example, mitomycin, adriamycin, doxorubicin, actinomycin, daunorubicin, idarubicin, pirarubicin, aclarubicin, epirubicin, peplomycin, zinostatin stimalamer and the like.
  • the antirheumatic drug can include, for example, methotrexate, sodium thiomalate, penicillamine, lobenzarit and the like.
  • the antithrombotic drug can include, for example, heparin, aspirin, antithrombin drug, ticlopidine, hirudin and the like.
  • the HMG-CoA reductase inhibitor can include, for example, cerivastatin, cerivastatin sodium, atorvastatin, atorvastatin calcium, rosuvastatin, rosuvastatin calcium, pitavastatin, pitavastatin calcium, fluvastatin, fluvastatin sodium, simvastatin, lovastatin, pravastatin, pravastatin sodium and the like.
  • the insulin resistance improver can include, for example, thiazolidine derivatives, such as troglitazone, rosiglitazone, pioglitazone and the like.
  • the ACE inhibitor can include, for example, quinapril, perindopril erbumine, trandolapril, cilazapril, temocapril, delapril, enalapril maleate, lisinopril, captopril and the like.
  • the calcium antagonist can include, for example, nifedipine, nilvadipine, diltiazem, benidipine, nisoldipine and the like.
  • the antihyperlipidemic drug can include, for example, bezafibrate, fenofibrate, ezetimibe, torcetrapib, pactimibe, K-604, implitapide, probucol and the like.
  • the integrin inhibitor can include, for example, AJM300.
  • the antiallergic drug can include, for example, tranilast and the like.
  • the antioxidant can include, for example, a-tocopherol, catechin, dibutylhydroxytoluene, butylhydroxyanisol and the like.
  • the GP IIb/IIIa antagonist can include, for example, abciximab and the like.
  • the retinoid can include, for Example, all-trans retinoic acid and the like.
  • the flavonoid can include, for example, epigallocatechin, anthocyanin, proanthocyanidin and the like.
  • the carotenoid can include, for example, ⁇ -carotene lycopene and the like.
  • the lipid improver can include, for example, eicosapentaenoic acid.
  • the DNA synthesis inhibitor can include, for example, 5-FU.
  • the tyrosine kinase inhibitor can include, for example, genistein, tyrphostin, erbstatin,staurosporine and the like.
  • the anti platelet drug can include, for example, ticlopidine, cilostazol, clopidogrel and the like.
  • the drug can include, for example, a steroid, dexamethasone, prednisolone and the like.
  • the tissue-derived biomaterial can include, for example, EGF (epidermal growth factor), VEGF (vascular endothelial growth factor), HGF (hepatocyte growth factor), PDGF (platelet derived growth factor), BFGF (basic fibroblast growth factor) and the like.
  • EGF epidermal growth factor
  • VEGF vascular endothelial growth factor
  • HGF hepatocyte growth factor
  • PDGF platelet derived growth factor
  • BFGF basic fibroblast growth factor
  • the interferon can include, for example, interferon-yl a.
  • the nitrogen monoxide promoting substance can include, for example, L-arginine.
  • the drug can include a drug that can be used to treat or cure stenosis and that can rapidly migrate into cells such as, for example, paclitaxel, docetaxel, sirolimus, everolimus, atorvastatin, and simvastatin, for example, paclitaxel.
  • the phospholipid is not necessarily specifically restricted.
  • the phospholipid can be a monomolecular compound from the standpoint of an ability to combine with the drug to form the solid dispersion and an ability to cause the drug to rapidly migrate into cells.
  • the phospholipid can be at least one species selected from the group including phosphatidylcholine, phosphatidylglycerol, phosphatidic acid, phosphatidylethanolamine, phosphatidylserine, phosphatidylinositol, phosphatidylinositol polyphosphoric acid, sphingomyelin, cardiolipin, partially hydrogenated product thereof, and completely hydrogenated product thereof.
  • the phospholipid can include at least one of phosphatidylcholine and completely hydrogenated product of phosphatidylcholine.
  • the phosphatidylcholine mentioned above can be one which has a C8-20 aliphatic acyl group so that it is hardly soluble in water but is wettable.
  • the aliphatic acyl group can be exemplified by octanoyl group, azelaoyl group, decanoyl group, lauroyl group, myristoyl group, palmitoyl group, stearoyl group, and oleoyl group.
  • the ratio of the phospholipid to the drug can be 10 to 200 mass%.
  • the ratio of the phospholipid is lower than 10 mass%, the phospholipid and the drug will not form the solid dispersion.
  • the ratio of the phospholipid higher than 200 mass% the resulting drug releasing layer is thick due to excessive phospholipid, which can be detrimental to smooth insertion into the body and smooth passage through the lesion.
  • An exemplary ratio of the phospholipid to the drug is 30 to 180 mass%, for example, 50 to 150 masts%, so that they form a solid solution which is an exemplary form of the solid dispersion.
  • the solid solution is defined as a form of solid dispersion in which one component is entirely dispersed in the other component at the molecular level as if the resulting system is chemically and physically uniform as a whole. For example, when the drug and the phospholipid for the solid solution, a beneficial effect can be produced.
  • An exemplary solid dispersion composed of the drug and the phospholipid may be examined for its structure by powder X-ray diffractometry (PXRD), differential scanning calorimetry (DSC), or solid nuclear magnetic resonance (NMR).
  • PXRD powder X-ray diffractometry
  • DSC differential scanning calorimetry
  • NMR solid nuclear magnetic resonance
  • the melting peak of the drug can disappear in DSC, for example, a thermogram of DSC performed on the solid dispersion has no endothermic peak due to the fusion of the drug.
  • the solid dispersion can be prepared by any suitable method.
  • An exemplary method includes dissolving the drug and the phospholipid in an organic solvent such as methanol, ethanol, chloroform, tetrahydrofuran, hexane, cyclohexane and the like, to give a solution containing 0.001 to 20 mass%, for example, 0.1 to 10 mass%, of the two components in total, and removing the organic solvent by drying in vacuum or with heating.
  • an organic solvent such as methanol, ethanol, chloroform, tetrahydrofuran, hexane, cyclohexane and the like
  • the solid dispersion of the drug and the phospholipid may be a porous body so that the phospholipid is easily wettable.
  • the porous body may be prepared in any suitable manner.
  • An exemplary method includes applying the solution containing the drug and the phospholipid to the medical device and removing the solvent used for the solution by freeze-drying with liquid nitrogen and the like.
  • the drug releasing layer can contain the solid dispersion composed of the drug and the phospholipid. It can also optionally contain pharmaceutical additives such as, for example, a stabilizer, antioxidant, filler and the like.
  • the drug releasing layer can partially or entirely cover the surface of the member constituting the medical device. In an exemplary embodiment, it can be sufficient for the drug releasing layer to partly cover the surface of the member constituting the medical device.
  • the drug releasing layer can have an adequate thickness which can be selected from the standpoint of ease with which the medical device approaches (is delivered to) the lesion, wherein the performance of the medical device can include stimulus to the blood vessel wall, and the effect of the released drug.
  • the drug releasing layer can have a thickness of 0.1 to 200 ⁇ m, for example, 1 to 100 ⁇ m, for example, 10 to 50 ⁇ m The thickness in this range can be suitable for the medical device for drug delivery to effectively release the drug when it comes into contact with the lumen of the living body. With such a thickness, the medical device for drug delivery can, for example, have a reduced outside diameter, and the medical device for drug delivery can smoothly approach the lesion and prevent restenosis without stimuli to the blood vessel wall.
  • the drug releasing layer may be formed in any suitable manner.
  • An exemplary method includes applying the solution containing the drug and the phospholipid to the surface of the medical device by means of microsyringe, microdispenser, ink jet, or spray, and subsequently removing the organic solvent used for the solution by drying in vacuum or with heating. In this way, for example, it is possible to form the solid dispersion composed of the drug and the phospholipid which functions as the drug releasing layer that covers at least partly the surface of the medical device in contact with the lumen tissue of the living body thereby manufacturing an exemplary medical device for drug delivery.
  • the surface of the base material such as balloon can be coated with an adhesive in advance and then the solution containing the drug and the phospholipid can be applied to the adhesive layer.
  • This procedure can be carried out in order to ensure good adhesion between the drug releasing layer which contains the solid dispersion composed of the drug and the phospholipid, and the surface of the balloon.
  • the coating material may contain a polymer having phospholipid on its side chains. Such a polymer can function as a good binder excelling in adhesion to the balloon and compatibility with the solid dispersion composed of the drug and the phospholipid.
  • the medical device for drug delivery can include any suitable structure.
  • it can include a hollow expandable body that expands after it has been inserted into the desired position.
  • it can be a balloon catheter, stent, snare-shaped wire, thrombus-removing basket or the like.
  • Fig. 6 is a side view of an exemplary balloon catheter as one example of a medical device for drug delivery.
  • Fig. 7 is a partly cut-away external view of the balloon catheter shown in Fig. 6 , with the proximal shaft 8 partly omitted and exemplary constituents enlarged.
  • Fig. 8 is an enlarged sectional view of the balloon taken along the line B-B in Fig. 7 .
  • the balloon catheter can be classified into two large categories: rapid exchange type and over-the-wire type.
  • Figs. 6 and 7 show the balloon catheter of rapid exchange type as an example. Exemplary aspects can be applied to balloon catheters of any suitable type. The following is a detailed description of exemplary constituents of an exemplary balloon catheter.
  • the exemplary balloon catheter 1 shown in Figs. 6 and 7 is that of a rapid exchange type. It is so designed as to be inserted into the blood vessel along the guide wire 3 or 6.
  • the balloon catheter 1 is composed of the hub 7, the proximal shaft 8, the intermediate part 9, the distal shaft 10, the balloon 21, and the inner shaft 11, which are sequentially arranged from the base end.
  • the hub 7 adjacent to the base end has the lure taper for connection with a compressing apparatus such as inflator.
  • the hub 7 is joined to the proximal shaft 8 which can be made of a comparatively stiff material such as metal or special plastics in such a way that a fluid can pass through the joint.
  • the proximal shaft 8 can be provided with the depth marker 2 that permits the operator to know easily how far the balloon catheter 1 has been inserted into the guiding catheter (not shown) during angioplasty.
  • the fore-end of the proximal shaft 8 is the reinforcing member 12. Between the reinforcing member 12 and the unworked part is an inflation opening that permits the fluid to flow across the wall of the proximal shaft 8.
  • the fluid forced in from the hub 7 flows from the inside to the outside of the proximal shaft 8 through the inflation opening.
  • the outside is in the lumen at the intermediate part 9.
  • the inflation opening may be omitted, in which case the fluid flows in the reinforcing member from the base end to the fore-end of the reinforcing member and flows into the outside (which is in the lumen at the distal shaft 10).
  • the fore-end of the proximal shaft 8 is connected to the intermediate part 9 in such a way that a fluid can pass through the connecting point.
  • the fore-end of the intermediate part 9 can be connected to the distal shaft 10 with comparatively low stiffness which is made of plastics in such a way that a fluid can pass through the connecting point.
  • the fore-end of the distal shaft 10 is connected to the base end of the balloon 21 in such a way that a fluid can pass through the connecting point.
  • the distal shaft 10 and the balloon 21 have the inner shaft 11 which passes through them coaxially.
  • the inner shaft 11 has the distal tip 13 at its fore-end.
  • the distal tip 13 extends from the fore-end of the balloon 21 and fluid-tightly joins with the fore-end of the balloon 21.
  • the base end of the inner shaft 11 extends to and fluid-tightly joins with the guide wire opening 4 which is formed at one part between the intermediate part 9 and the distal shaft 10.
  • the guide wire 3 or 6 in Fig. 6 passes the inner shaft 11 from the fore-end opening of the distal tip 13 to the guide wire opening 4.
  • the inner shaft 11 inside the balloon 21 can have contrast markers 5 on its periphery.
  • the balloon 21 remains collapsed around the inner shaft 11 when it is not yet expanded. Alter expansion, the balloon 21 can take on a cylindrical shape at its center so that it easily expands the stenosed part of the blood vessel.
  • the central part of the balloon 21 does not always need to be completely cylindrical but it may be polygonal columnar.
  • the contrast markers 5 can permit the operator to easily locate the balloon 21 at the stenos part by X-ray radioscopy for angioplasty.
  • the exemplary balloon catheter shown in Figs. 6 and 7 is that of double-tube structure including the distal shaft 10 and the inner shaft 11, However, it may be constructed such that the inner shaft is replaced by a solid rod-like supporting member without being restricted the foregoing structure.
  • An exemplary balloon can be formed from a cylindrical balloon film 23 having a thickness of about 5 to 50 ⁇ m. The balloon expands and shrinks as it is supplied with and emptied of the compressed fluid that passes through the lumen 24, which is a space existing between the outside of the inner shaft and the inside of the distal shaft, as shown in Fig. 8 .
  • the exemplary balloon of the exemplary balloon catheter has a hollow sectional structure as shown in Fig. 8 . It has the balloon film 23 coaxially surrounding the inner shaft 11, and the balloon film 23 is coated with the drug releasing layer 22 which contains the solid dispersion composed of the drug and the phospholipid.
  • An exemplary balloon film constituting the balloon can be formed from a slightly material so that it can expand the stenosed part of the blood vessel.
  • a slightly material such as polyolefin (such as polyethylene, polypropylene, polybutene, ethylene-propylene copolymer, ethylene-vinyl acetate copolymer, ionomer and the like), crosslinked polyolefin, polyester (such as polyethylene terephthalate and the like), polyester elastomer, polyvinyl chlorine, polyurethane, polyurethane elastomer, polyphenylenesulfide, polyamide, polyamide elastomer, polymeric material such as fluoroplastics and the like, silicone rubber, latex robber and the like. These polymeric materials may be used in the form of laminate film.
  • the balloon 21 may be formed separately to be attached to the tip of the distal shaft 10 by biaxially-oriented blow moulding, or it may be formed integral with the tip of the distal shaft 10 by
  • the balloon 21 can be formed such that its cylindrical part in its expanded state has an outside diameter of, for example, 1.0 to 10 mm, for example, 1.0 to 5.0 mm, and a length of 5 to 50 mm, for Example, 10 to 40 mm, with the overall length being, for example, 10 to 70 mm, for example, 15 to 60 mm.
  • the balloon catheter may be produced by any suitable method.
  • Exemplary methods include a dripping method including dripping a mold in a solution of raw material, whereby forming the balloon film on the mo!d, followed by drying and denoting, and a blow moulding method including blowing a parison, thereby forming the balloon film.
  • Example and Comparative Examples 1 to 3 each mixture with the composition shown in Table 1 was dissolved in 0.5 mL of ethanol or acetone.
  • Comparative Example 4 10 mg of paclitaxel alone was dissolved in 0.5 mL of acetone.
  • the paclitaxel is a product of SIGMA Corp.
  • the thus prepared solution was completely freed of ethanol or acetone by vacuum drying.
  • the resulting dry product was placed in an aluminum pan and thereafter underwent DSC in a nitrogen atmosphere at a heating rate of 10°C/min.
  • the apparatus used for DSC is Diamond DSC made by Perkin Elmer Inc. The results are shown in Table 1.
  • Example 12 and Comparative Example 10 each of the solution of HSPC and paclitaxel and the solution of BHA and paclitaxel, which were prepared in Example 1 and Comparative Example 3, respectively, was applied to the external surface of the balloon member of the balloon catheter (made by Terumo Corporation).
  • the balloon member is cylindrical in shape, measuring 3.0 mm in outside diameter and 20 mm in length, and is made of polyamide. Coating was accomplished by using a microsyringe pump (mad by KD Scientific), with the balloon catheter rotating. This coating step was followed by vacuum drying to completely remove ethanol or acetone thereby forming a coating layer.
  • the thus coated balloon was enclosed in a stent (made by Terumo Corporation), which was subsequently crimped.
  • the balloon catheter havin the crimped stent was sterilized with ethylene oxide gas.
  • Comparative Example 11 the same procedure as above was repeated except that the solution was replaced by the solution of paclitaxel alone which was prepared in Comparative Example 1.
  • the sterilized balloon catheter was examined for the amount of paclitaxel carried thereon by means of high-performance liquid chromatography (HPLC, made by Shimadzu Corporation). The results are as follows. 529 ⁇ g in Examples 12 which employed the solution of HSPC and paclitaxel. 514 ⁇ g in Comparative Examples 10 which the solution of BHA and paclitaxel. 548 ⁇ g in Comparative Example 11 which employed the solution of paclitaxel alone.
  • the solid solution of HSPC and paclitaxel permits paclitaxel to migrate to the blood vessel tissue much more efficiently than the solution of paclitaxel alone.
  • the solid solution of BHA and paclitaxel does not differ from the solution of paclitaxel alone.
  • a possible reason for this is that the solid solutions differ in water wettability. That is, the solid solution of BHA and paclitaxel is hardly wettable and hence unable to adhere to the blood vessel tissue, whereas the solid solution of HSPC and paclitaxel easily becomes wet upon contact with water and adheres to the blood vessel tissue and stays on the surface of the blood vessel. As a result, the solid solution of HSPC and paclitaxel is assumed to be liable to migrate to the tissue.
  • thermogram for Comparative Example 12 has an endothermic peak at about 185°C due to fusion of sirolimus
  • Fig. 9 shows that the thermogram for Example 13 does not have an endothermic peak due to fusion of sirolimus.
  • Fig. 12 shows that the thermogram for Comparative Example 13 has an endothermic peak at about 140°C due to fusion of simvastatin
  • Fig. 10 shows that the thermogram for Example 14 does not have an endothermic peak due to fusion of simvastatin.
  • HSPC is highly compatible with not only paclitaxel but also sirolimus and simvastatin and forms a solid solution with them.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Anesthesiology (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Vascular Medicine (AREA)
  • Surgery (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Transplantation (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Materials For Medical Uses (AREA)
  • Media Introduction/Drainage Providing Device (AREA)
EP10811665.8A 2009-08-27 2010-08-03 Instrument médical pour administrer un médicament Withdrawn EP2452701A4 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2009196679 2009-08-27
PCT/JP2010/063096 WO2011024614A1 (fr) 2009-08-27 2010-08-03 Instrument médical pour administrer un médicament

Publications (2)

Publication Number Publication Date
EP2452701A1 true EP2452701A1 (fr) 2012-05-16
EP2452701A4 EP2452701A4 (fr) 2014-04-23

Family

ID=43627724

Family Applications (1)

Application Number Title Priority Date Filing Date
EP10811665.8A Withdrawn EP2452701A4 (fr) 2009-08-27 2010-08-03 Instrument médical pour administrer un médicament

Country Status (5)

Country Link
US (1) US20120082706A1 (fr)
EP (1) EP2452701A4 (fr)
JP (1) JP5480272B2 (fr)
CN (1) CN102470196A (fr)
WO (1) WO2011024614A1 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130288951A1 (en) * 2012-04-27 2013-10-31 Biomet Manufacturing Corp. Compositions and methods for coating implant surfaces to inhibit surgical infections
EP2841117B1 (fr) * 2012-04-27 2019-11-27 Biomet Manufacturing, LLC Compositions et procédés de revêtement de surfaces d'implants pour inhiber les infections chirurgicales
US9775853B2 (en) 2013-03-15 2017-10-03 Biomet Manufacturing, Llc. Hemostatic compositions and methods
US11406742B2 (en) 2014-07-18 2022-08-09 M.A. Med Alliance SA Coating for intraluminal expandable catheter providing contact transfer of drug micro-reservoirs
US9492594B2 (en) 2014-07-18 2016-11-15 M.A. Med Alliance SA Coating for intraluminal expandable catheter providing contact transfer of drug micro-reservoirs
JP6486627B2 (ja) 2014-08-12 2019-03-20 国立大学法人 鹿児島大学 食道狭窄を治療及び／又は予防するための医薬組成物
JP6831721B2 (ja) * 2017-03-16 2021-02-17 テルモ株式会社 バルーンカテーテルの製造方法および製造装置
WO2019238841A1 (fr) * 2018-06-15 2019-12-19 Københavns Universitet Revêtement de dispositifs médicaux pour éviter la prolifération des fibroblastes
CN110292701B (zh) * 2019-06-27 2021-11-16 山东瑞安泰医疗技术有限公司 一种药物洗脱球囊导管及其制备方法
CN111671982A (zh) * 2020-05-08 2020-09-18 北京永益润成科技有限公司 一种药物涂层组合物及其制备方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030068355A1 (en) * 2001-08-20 2003-04-10 Shanley John F. Therapeutic agent delivery device with protective separating layer
US20080255509A1 (en) * 2006-11-20 2008-10-16 Lutonix, Inc. Medical device rapid drug releasing coatings comprising oils, fatty acids, and/or lipids
US20090054837A1 (en) * 2006-02-09 2009-02-26 B. Braun Melsungen Ag Coating Method for a Folded Balloon

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0032622B1 (fr) * 1979-12-20 1985-08-14 Dennis Chapman Phospholipides polymérisables et leurs polymères, procédés pour leur préparation, procédés pour leur utilisation dans le revêtement de substrats et la formation de liposomes et substrats revêtus et compositions de liposomes ainsi obtenus
GB9022938D0 (en) * 1990-10-22 1990-12-05 Biocompatibles Ltd Non-thrombogenic surfaces
US5136017A (en) 1991-02-22 1992-08-04 Polysar Financial Services S.A. Continuous lactide polymerization
GB9112267D0 (en) * 1991-06-07 1991-07-24 Biocompatibles Ltd Polymeric coating
EP0639989B1 (fr) * 1992-04-24 2001-06-27 Biocompatibles Limited Procede pour diminuer l'adherence de micro-organismes
JP3399986B2 (ja) * 1992-09-22 2003-04-28 住友ベークライト株式会社 血液適合性材料の製造方法
US5464650A (en) 1993-04-26 1995-11-07 Medtronic, Inc. Intravascular stent and method
CN1124165A (zh) * 1994-12-05 1996-06-12 北京医科大学 脂质体球囊导管——一种新的管腔内基因和药物运载体系
US6120536A (en) * 1995-04-19 2000-09-19 Schneider (Usa) Inc. Medical devices with long term non-thrombogenic coatings
US6066602A (en) * 1997-08-07 2000-05-23 Becton Dickinson And Company Waterborne non-silicone lubricant comprising phospholipid and polyether
JP3700440B2 (ja) * 1999-01-19 2005-09-28 ニプロ株式会社 抗血栓性医療用具およびその製造方法
CN1390149A (zh) * 1999-10-06 2003-01-08 宾夕法尼亚州研究基金会 避免人体脉管再狭窄的系统和器具
DE60129578T2 (de) 2000-10-31 2008-04-03 Med Institute, Inc., West Lafayette Beschichtete, implantierbare medizinische geräte
DE10115740A1 (de) 2001-03-26 2002-10-02 Ulrich Speck Zubereitung für die Restenoseprophylaxe
JP4886939B2 (ja) * 2001-07-19 2012-02-29 真也 岡崎 生体内留置用ヨウ素放出性治療材料およびステント
WO2003026492A2 (fr) * 2001-09-28 2003-04-03 Esperion Therapeutics Inc. Prevention et traitement de la restenose par l'administration locale d'un medicament
DE10244847A1 (de) 2002-09-20 2004-04-01 Ulrich Prof. Dr. Speck Medizinische Vorrichtung zur Arzneimittelabgabe
DE10307205A1 (de) * 2003-02-20 2004-09-09 Jostra Ag Blutverträgliche Beschichtung von Kunststoffoberflächen
JP2004248904A (ja) * 2003-02-20 2004-09-09 Toyobo Co Ltd 医療用組成物
CN100371032C (zh) * 2004-01-16 2008-02-27 东南大学 防再狭窄药物缓释型血管支架及其制备方法
EP1916006A1 (fr) * 2006-10-19 2008-04-30 Albert Schömig Implant revêtu de cire ou de résine
US20080181928A1 (en) * 2006-12-22 2008-07-31 Miv Therapeutics, Inc. Coatings for implantable medical devices for liposome delivery
CN101185779B (zh) * 2007-12-19 2010-06-02 上海赢生医疗科技有限公司 一种药物缓释支架的制备方法

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030068355A1 (en) * 2001-08-20 2003-04-10 Shanley John F. Therapeutic agent delivery device with protective separating layer
US20090054837A1 (en) * 2006-02-09 2009-02-26 B. Braun Melsungen Ag Coating Method for a Folded Balloon
US20080255509A1 (en) * 2006-11-20 2008-10-16 Lutonix, Inc. Medical device rapid drug releasing coatings comprising oils, fatty acids, and/or lipids

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO2011024614A1 *

Also Published As

Publication number Publication date
CN102470196A (zh) 2012-05-23
JP5480272B2 (ja) 2014-04-23
JPWO2011024614A1 (ja) 2013-01-31
EP2452701A4 (fr) 2014-04-23
US20120082706A1 (en) 2012-04-05
WO2011024614A1 (fr) 2011-03-03

Similar Documents

Publication Publication Date Title
EP2452701A1 (fr) Instrument médical pour administrer un médicament
JP6157543B2 (ja) 封入薬物組成物およびその使用方法
JP6038912B2 (ja) シロリムスを制御放出するためのシロリムスコーティングされたカテーテルバルーンを有するバルーンカテーテル
US9610386B2 (en) Method for electrostatic coating of a medical device
EP1663343B1 (fr) Application d'une substance therapeutique sur une zone tissulaire au moyen d'un dispositif medical extensible
RU2447901C2 (ru) Медицинский продукт для лечения обтураций просветов организма и для предупреждения угрожающих повторных обтураций
KR101550470B1 (ko) 개선된 약제학적으로 코팅된 의약, 이의 제조 방법 및 이의 용도
JP2018122120A (ja) 非血管狭窄のための薬物被覆バルーンカテーテル
CN106794285B (zh) 用于药物释放的医疗装置的可移除覆盖物
CN105263538B (zh) 设有微孔和金属网的导管球囊
JP6141982B2 (ja) 弁形成のためのバルーン表面被覆
WO2006109668A1 (fr) Systeme de stent pour enrobage de medicament et procede de production
JP2007097706A (ja) ステント
JP5684863B2 (ja) 生体内留置物
US20140172114A1 (en) Stent delivery system and method using the same
JP2022508608A (ja) 高圧でミセルを注入するためのバルーン・カテーテル・システム
JP2004041704A (ja) ステント

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20111205

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR

DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20140321

RIC1 Information provided on ipc code assigned before grant

Ipc: A61L 31/16 20060101ALI20140317BHEP

Ipc: A61L 31/00 20060101AFI20140317BHEP

Ipc: A61L 29/16 20060101ALI20140317BHEP

Ipc: A61M 25/00 20060101ALI20140317BHEP

17Q First examination report despatched

Effective date: 20141204

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20150425